<DOC>
	<DOC>NCT01069822</DOC>
	<brief_summary>The main purpose of this study is to evaluate the effect repeated doses of AZD6765 (a drug being developed for the treatment of patients with severe major depressive disorder) has on the PK (pharmacokinetic) profile of Midazolam. (The PK profile is how the drug leaves your body and acts in the body.)</brief_summary>
	<brief_title>A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>BMI between 1930 Significant result for CSSRS at screening or baseline Single arm preference for IV procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Midazolam</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>